EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC

Qi Yang iD, Bao Xue, Xianjie Qiu, Kaixin Yang, Jielin Tang, Anqi Zhou, Jingjing Zou iD, Yuhan Mao, Jiayi Zhong, Yuan Zhou, Wei Zhang, Qiong Zhang iD und 10 weitere

Journal of Virology · 2026

DOI: 10.1128/jvi.01487-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2026. Verfasst von Qi Yang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus, Human, Antiviral Agents, Viral Fusion Proteins, Drug Resistance, Viral. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Project of Guangzhou Laboratory, Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lonafarnib, an oral antiviral that targets the fusion glycoprotein of respiratory syncytial virus (RSV), has demonstrated efficacy in vitro and in vivo . However, because the RSV has evolved to become resistant to other fusion inhibitors, there is a concern that the same could occur for lonafarnib. Here, we identified resistance to lonafarnib in the RSV A2 strain and a recent clinical isolate, RSV ON1, via in vitro selection at scale. Cell‒cell fusion and recombinant live RSV analysis confirmed that the mutations at K394, K399, and T400 of the cysteine-rich region of the fusion protein mediate high-level resistance. Lonafarnib resistance mutations also confer cross-resistance to other fusion inhibitors of clinical interest. All-atom molecular dynamics simulations revealed that these resistance mutations confer reduced stability to the fusion protein, thereby diminishing its binding affinity with lonafarnib. To address this vulnerability proactively and increase the barrier to resistance development, we designed the first potent proteolysis-targeting chimera (PROTAC) fusion protein degrader, compound 0179841, which uses lonafarnib and cereblon as ligands. This PROTAC effectively inhibited RSV replication. Collectively, our findings indicate that RSV develops resistance to lonafarnib in the cysteine-rich region of the fusion protein. This work sheds light on the mechanisms by which RSV evolves resistance to lonafarnib and provides a foundation for the rational design of antivirals aimed at preventing resistance. IMPORTANCE Respiratory syncytial virus (RSV) infection poses a substantial public health challenge. Resistance to several potent fusion inhibitors, which are currently in various stages of clinical development, can readily emerge. Through a drug repurposing screen, we identified lonafarnib as an RSV fusion inhibitor; however, concerns exist regarding the potential development of resistance. Here, large-scale in vitro selection experiments revealed specific mutations within the highly conserved cysteine-rich region of the fusion (F) protein that confer high-level lonafarnib resistance across diverse RSV strains. These resistance mutations also confer cross-resistance to other clinical-stage fusion inhibitors. Mechanistic investigations demonstrated that these mutations reduce F protein stability, thereby diminishing the binding affinity of lonafarnib. As a proof of concept for an alternative antiviral strategy, we rationally designed the first potent proteolysis-targeting chimera (PROTAC) F protein degrader, compound 0179841, by utilizing lonafarnib and cereblon ligands. This novel antiviral agent effectively inhibits RSV infection by inducing degradation of the F protein. This work elucidates the molecular basis of RSV resistance to lonafarnib and establishes a strategy for developing next-generation antivirals aimed at preempting resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus, HumanAntiviral AgentsViral Fusion ProteinsDrug Resistance, ViralPyridinesHumansMutationMolecular Dynamics SimulationCysteineRespiratory Syncytial Virus Infections

Stichwörter der Autor:innen

fusion glycoproteinlonafarnibproteolysis-targeting chimeraresistant mutationsrespiratory syncytial virus

Substanzen

Antiviral AgentsViral Fusion ProteinsPyridinesCysteine

Autor:innen und Institutionen

  • Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
  • State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
  • Chinese Academy of Sciences, Wuhan Institute of Virology, Wuhan, P.R. China.
  • College of Life Sciences, University of Chinese Academy of Sciences, Beijing, P.R. China.
  • State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, Guangdong, P.R. China.
  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.

ORCID-Profile: Qi Yang, Jingjing Zou, Qiong Zhang, Wei Peng, Jinsai Shang, Xi Xu, Yixue Li, Xinwen Chen

Förderung

  • Major Project of Guangzhou Laboratory
  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • Peal River Talent Recruitment Program

Zitieren

APA

Yang, Q., Xue, B., Qiu, X., Yang, K., Tang, J., Zhou, A., Zou, J., Mao, Y., Zhong, J., Zhou, Y., Zhang, W., Zhang, Q., Xiao, Q., Tang, W., Li, Z., Ye, W., Zou, G., Peng, W., Shang, J., …, & Chen, X. (2026). Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC. Journal of Virology. https://doi.org/10.1128/jvi.01487-25

Vancouver

Yang Q, Xue B, Qiu X, Yang K, Tang J, Zhou A, et al. Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC. Journal of Virology. 2026. doi:10.1128/jvi.01487-25

BibTeX
@article{Yang2026,
  author = {Yang, Qi and Xue, Bao and Qiu, Xianjie and Yang, Kaixin and Tang, Jielin and Zhou, Anqi and Zou, Jingjing and Mao, Yuhan and Zhong, Jiayi and Zhou, Yuan and Zhang, Wei and Zhang, Qiong and Xiao, Qingyu and Tang, Wei and Li, Zhiyu and Ye, Wencai and Zou, Gang and Peng, Wei and Shang, Jinsai and Xu, Xi and Li, Yixue and Chen, Xinwen},
  title = {Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC},
  journal = {Journal of Virology},
  year = {2026},
  doi = {10.1128/jvi.01487-25}
}
Kostenlos starten →